CEMPRA, INC. (NASDAQ:CEMP) Files An 8-K Other Events
Item8.01 Other Events.
On February24, 2017, we issued a press release to report positive
topline results from a phase 3 study of oral fusidic acid in
patients with acute bacterial skin and skin structure infections.
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
Item9.01. Financial Statements and Exhibits.
| (d) | Exhibits |
|
ExhibitNo. |
Description |
|
| 99.1 | Press release dated February 24, 2017. |
About CEMPRA, INC. (NASDAQ:CEMP)
Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI). CEMPRA, INC. (NASDAQ:CEMP) Recent Trading Information
CEMPRA, INC. (NASDAQ:CEMP) closed its last trading session 00.00 at 3.15 with 981,516 shares trading hands.
